Treatment of Severe Preeclampsia with Antithrombin Concentrate: Results of a Prospective Feasibility Study

ABSTRACT

The prospective feasibility study was designed to determine whether treatment with antithrombin (AT) concentrates could be used for patients with severe preeclampsia to provide clinical efficacy without the full systemic antihypertensive drug. Twenty-nine severe preeclamptic patients (24 to 36 weeks of gestation, gestosis index [GI] ≥ 6 points) were randomized to receive AT (1500 U/day) or not. AT was given intravenously once daily for 7 consecutive days. Twenty-four hours of continuous infusion of 5000 U/day of unfractionated heparin was given simultaneously in both groups. There were no statistical differences in the clinical profiles of the two groups. Maternal symptoms were evaluated from the difference of GI before and after treatment, and fetal findings were evaluated from the changes of the biophysical profile score. Improvement was significantly greater in the AT group for both the GI (P = 0.046) and the biophysical profile score (P = 0.022). The improvement of coagulation parameters was also evaluated. The improvement of plasmin-plasmin inhibitor complex (PPIC), D-dimer levels, and platelet counts was observed in the AT group compared with the non-AT group. The coagulation index as a composite coagulation test parameter showed a significantly improvement in the AT group. No adverse events related to AT were observed. Given that AT plus heparin was significantly better than treatment with heparin alone for improvement of both GI and biophysical profile of infant, it is suggested that therapy with AT alone might be effective enough for severe preeclampsia.

KEYWORDS

Preeclampsia - hypercoagulable state - vasoconstriction - antithrombin (AT) concentrate - biophysical profile

REFERENCES

• 1 Mushambi M C, Halligan A W, Williamson K. Recent developments in the pathophysiology and management of pre-eclampsia.  Br J Anaesth . 1996;  76 133-148
• 2 Rabiet M J, Plantier J L, Dejana E. Thrombin-induced endothelial cell dysfunction.  Br Med Bull . 1992;  50 936-965
• 3 Kobayashi T, Tokunaga N, Sugimura M, Kanayama N, Terao T. Vasospasms are characteristic in cases with eclampsia/preeclampsia and HELLP syndrome:proposal of angiospastic syndrome of pregnancy.  Semin Thromb Hemost . 2001;  27 131-135
• 4 Kobayashi T, Sugimura M, Naruse H. et al . Anticholinergics induce eclamptic seizures.  Semin Thromb Hemost . 2002;  28 511-514
• 5 Terao T, Maki M, Ikenoue T. et al . The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy.  Gynecol Obstet Invest . 1991;  31 74-85
• 6 Perry K G, Martin J N. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia.  Clin Obstet Gynecol . 1992;  35 338-350
• 7 Weiner C P, Brandt J. Plasma antithrombin III activity: an aid in the diagnosis of preeclampsia-eclampsia.  Am J Obstet Gynecol . 1982;  142 275-281
• 8 Kobayashi T, Sugimura M, Kanayama N. et al . Coagulation/ fibrinolysis disorders in patients with severe preeclampsia.  Semin Thromb Hemost . 1999;  25 451-454
• 9 Kobayashi T, Tokunaga N, Sugimura M, Kanayama N, Terao T. Predictive values of coagulation/fibrinolysis parameters for the termination of pregnancy complicated by severe preeclampsia.  Semin Thromb Hemost . 2001;  27 137-141
• 10 Kobayashi T, Sumimoto K, Tokunaga N. et al . Coagulation index to distinguish severe preeclampsia from normal pregnancy.  Semin Thromb Hemost . 2002;  28 495-499
• 11 Weenink G H, Treffers P E, Vijin P, Smorenberg-Schoorl M E, ten Cate W J. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity.  Am J Obstet Gynecol . 1984;  148 1092-1097
• 12 He S, Bremme K, Blombäck M. Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia.  Blood Coagul Fibrinolysis . 1997;  8 232-238
• 13 The Japan Society of Obstetrics and Gynecology. The definition of pre-eclampsia in Japan.  Acta Obstet Gynaecol Jpn . 1992;  44 5-6
• 14 Von Goecke C, Schwabe G. Vorschlag einer Stadien-Einteilung der Gestose.  Zbl Gynäk . 1965;  87 1439-1443
• 15 Jürgens H, Dichmann R. Gestosis index and perinatal mortality.  Zbl Gynäk . 1975;  97 1201-1211
• 16 Kaminski K, Rechberger T. Concentration of digoxin-like immunoreactive substance in patients with preeclampsia and its relation to severity of pregnancy-induced hypertension.  Am J Obstet Gynecol . 1991;  165 733-736
• 17 Manning F A, Lange I R, Morrison I, Harman C R. Fetal biophysical profile score and the nonstress test: a comparative trial.  Obstet Gynecol . 1984;  64 326-331
• 18 Harpel P C. Blood proteolytic enzyme inhibitors: their role in modulating blood coagulation and fibrinolytic enzyme pathways. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis Philadelphia: J.B. Lippincott 1982: 738-741
• 19 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor.  J Biol Chem . 1973;  248 6490-6405
• 20 Shinyama H, Akira T, Uchida T, Hirahara K, Watanabe M, Kagitani Y. Antithrombin III prevents renal dysfunction and hypertension induced by enhanced intravascular coagulation in pregnant rats: pharmacological confirmation of the benefits of treatment with antithrombin III in preeclampsia.  J Cardiovasc Pharmacol . 1996;  27 702-711
• 21 Maki M, Terao T, Ikenoue T. et al . Clinical evaluation of antithrombin III concentrate (BI6.013) for disseminated intravascular coagulation in obstetrics.  Gynecol Obstet Invest . 1987;  23 230-240
• 22 Fujiwara K, Okita K, Akamatsu K. et al . Antithrombin III concentrate in the treatment of fulminant hepatic failure.  Gastroenterol Jpn . 1988;  23 423-427
• 23 Weenink G H, ten Cate W J, Treffers P E. Hypertensive disorders.  Clin Obstet Gynecol . 1985;  28 37-45
• 24 Terao T, Kobayashi T, Imai N, Oda H, Karasawa T. Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment with AT-III concentrate.  Asia-Oceania J Obstet Gynecol . 1989;  15 25-32
• 25 Kwawukume E Y, Ghosh T S. Oral nifedipine therapy in the management of severe preeclampsia.  Int J Gynecol Obstet . 1995;  49 265-269
• 26 Sibai B M. Treatment of hypertension in pregnant women.  N Engl J Med . 1996;  335 257-265
• 27 Montan S. Medical prevention of pre-eclampsia.  Acta Obstet Gynecol Scand Suppl . 1997;  164 111-115
• 28 Wacker J, Werner P, Walter-Sank I, Bastert G. Treatment of hypertension in patients with preeclampsia: a prospective parallel-group study comparing dihydralazine with urapidil.  Nephrol Dial Transplant . 1998;  13 318-325
• 29 Sibai B M. Prevention of preeclampsia: a big disappointment.  Am J Obstet Gynecol . 1998;  179 1275-1278
• 30 Marcus A J. Platelet aggregation. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis Philadelphia: J.B. Lippincott 1982: 380-389.
• 31 White R P, Chapleau C E, Dngdale M, Robertson J T. Cerebral arterial contractions induced by human and bovine thrombin.  Stroke . 1980;  11 363-368.
• 32 Fenton J W. Thrombin specificity.  Ann N Y Acad Sci . 1981;  370 468-495
• 33 Minnear F L, Martin D, Hill L, Taylor A E, Malik A B. Lung morphological and permeability changes induced by intravascular coagulation dogs.  Am J Physiol . 1987;  253 H634-H644
• 34 Zimmerman G A, Mclntyre T M, Prescott S M. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro.  J Clin Invest . 1985;  76 2235-2246
• 35 Mutoh S, Komatsu Y, Kobayashi M. et al . Plasma coagulation-fibrinolysis system in the utero-placental circulation in severe preeclampsia: especially on tPA/PAI-1/C and active PAI-1.  Jpn J Thromb Hemost . 1994;  5 54-65